Affiliation:
1. Faculty of Technology and Metallurgy, Belgrade
Abstract
Oxaprozin (3-(4,5-difeniloksazol-2-yl)propanoic acid) is a nonsteroidal
anti-inflammatory drug (NSAID) used in the treatment of numerous inflammatory
musculoskeletal diseases, including rheumatoid arthritis, osteoarthritis,
tendonitis, ankylosing spondylitis and bursitis. It is the first
representative member of the diaryl-substituted heterocyclic compounds, which
have found clinical use as selective cyclooxygenase-2 (COX-2) inhibitors.
U.S. Food and Drug Administration (FDA) approved its official use in 1992.
Both anti-inflammatory and analgesic properties of oxaprozin are mainly due
to the potent inhibition of COX. However, oxaprozin-induced benefits might be
also regulated by other COX-independent pathways. It has been shown that
oxaprozin induced direct proapoptotic effects in CD40L-treated human
monocytes independently of COX inhibition. It also has several advantages in
the treatment of inflammatory diseases in comparison to other NSAIDs such as
aspirin, naproxen, indomethacin and phenylbutazone, which enabled oxaprozin
to become one of the most used NSAIDs in America. Oxaprozin, as other members
of the group of NSAIDs, can cause gastrointestinal complications, but
significantly lower due to relatively high pKa value. In this paper,
importance of oxaprozin in the treatment of arthritis and its pharmacokinetic
properties were described, therewith its activity and side effects were
compared with other commercially available anti-inflammatory drugs.
Publisher
National Library of Serbia
Subject
General Chemical Engineering,General Chemistry
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献